The expiration of primary patents for original formulations has dramatically transformed the structural framework of the Docetaxel Market over the past several years. The influx of multiple generic versions has introduced healthy market competition, resulting in a substantial reduction in the per-vial cost of this critical chemotherapeutic agent. This price adjustment has proved deeply...